Pactimibe
Alternative Names: CS 505Latest Information Update: 24 Oct 2021
At a glance
- Originator Daiichi Sankyo Inc; Kyoto Pharmaceutical Industries
- Developer Daiichi Sankyo Europe; Daiichi Sankyo Inc
- Class Antihyperlipidaemics; Indoleacetic acids; Small molecules
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 26 Oct 2005 Discontinued - Phase-I for Atherosclerosis in Japan (PO)
- 26 Oct 2005 Discontinued - Phase-II/III for Atherosclerosis in Europe (PO)